Bridge Global Pharmaceuticals

Bridge Global Pharmaceuticals was a pharmaceutical company based in Gaithersburg, Maryland, that was active in the mid-to-late 2000s. The company focused on the development of novel oncology therapeutics, specifically targeting DNA topoisomerase I. It collaborated with the National Cancer Institute (NCI) on the evaluation of indenoisoquinoline derivatives, such as NSC 724998, for cancer treatment. Bridge Global Pharmaceuticals was involved in preclinical studies and pharmacokinetic modeling to advance these candidates toward clinical trials. The company is no longer active and appears to have ceased operations after its initial research phase.